title: Tolerability of antihypertensive drugs in a community-based setting.
abstract: BACKGROUND
  Outside the experimental environment of clinical trials, the tolerability of angiotensin-converting enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), and the angiotensin II antagonist losartan has not been compared.
  
  
  OBJECTIVE
  The purpose of this study was to estimate, in current clinical practice, the 3-month cumulative incidence of side effects among first-time users of losartan, ACEIs, and CCBs for hypertension.
  
  
  METHODS
  We conducted a prospective cohort study through a network of 173 pharmacies across Canada to identify patients with hypertension who were newly prescribed monotherapy with losartan, an ACEI, or a CCB. Individuals were interviewed by telephone 3 times over a 3-month period to determine perceived side effects of the antihypertensive medication prescribed. Data were analyzed using a multivariate logistic regression model.
  
  
  RESULTS
  Among the 663 eligible individuals, the 3-month cumulative incidence of perceived side effects was 52.5% (42/80), 60.2% (222/369), and 69.6% (149/214) for those treated with losartan, an ACEI, and a CCB, respectively. After adjustment for sex, age, level of education, number of symptoms perceived the week before entering the study, prior use of antihypertensive drugs, current use of any other drug, drug insurance coverage, and duration of hypertension, the odds of reporting a side effect were significantly higher among patients treated with an ACEI (odds ratio [OR] = 1.78: 95% CI, 1.02-3.12) or a CCB (OR = 2.65; 95% CI, 1.47-4.78) compared with patients treated with losartan.
  
  
  CONCLUSIONS
  In a community-based setting, we observed that losartan is better tolerated than ACEIs and CCBs. Given that the occurrence of side effects may contribute to lower adherence to drug treatment, the low incidence of side effects associated with losartan makes it an attractive antihypertensive drug choice.
authors.affiliation: Epidemiology Research Group and Faculty of Pharmacy, Laval University, Quebec City, Québec, Canada. jean-pierre.gregoire@pha.ulaval.ca
authors.forename: J P
authors.initials: JP
authors.lastname: Grégoire
authors.forename: J
authors.initials: J
authors.lastname: Moisan
authors.forename: R
authors.initials: R
authors.lastname: Guibert
authors.forename: A
authors.initials: A
authors.lastname: Ciampi
authors.forename: A
authors.initials: A
authors.lastname: Milot
authors.forename: I
authors.initials: I
authors.lastname: Côté
authors.forename: M
authors.initials: M
authors.lastname: Gaudet
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D002170:Canada; D015331:Cohort Studies; D003157:Community Pharmacy Services / Q000706:statistics & numerical data*; D004363:Drug Utilization; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D015994:Incidence; D016015:Logistic Models; D019808:Losartan / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010349:Patient Compliance; D011446:Prospective Studies; D012959:Socioeconomic Factors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D019808:Losartan